04:21 PM EST, 12/23/2025 (MT Newswires) -- Solventum ( SOLV ) said late Tuesday it closed the acquisition of Acera Surgical for $725 million in upfront cash with provisions for up to $125 million in milestone-based payments.

The addition of Acera's synthetic tissue matrix technology will expand Solventum's ( SOLV ) wound care portfolio, the company said.

The transaction is expected to be slightly dilutive to adjusted EPS in 2026 and accretive to adjusted EPS starting in 2027, according to a statement.

The transaction is expected to be immaterial to Q4 results, according to the company.